Document is current
Any future updates will be listed below
-
Authors
Gong, Ze
Li, Jia
He, Zijun
Li, Shilin
Cao, Peihua
Ruan, Guangfeng
Zhang, Yan
Zeng, Qing
Chen, Rong
Zheng, Peng
Fan, Tao
Zhao, Yijin
Lu, Pengcheng
Zhu, Zhaohua
Huang, Guozhi
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82103903, 82002380, 82072528)
Basic and Applied Basic Research Foundation of Guangdong Province (2019A1515111169)
- License Information
-
More Information
Article History
Received: 30 April 2022
Accepted: 6 July 2022
First Online: 17 August 2022
Declarations
:
: The OAI study was approved by institutional review boards at each OAI clinical site and the coordinating center: Memorial Hospital of Rhode Island Institutional Review Board, The Ohio State University’s Biomedical Sciences Institutional Review Board, University of Pittsburgh Institutional Review Board, University of Maryland Baltimore – Institutional Review Board, and Committee on Human Research at University of California, San Francisco. All participants provided written informed consent. The Tufts Medical Center Institutional Review Board deemed that the work done at our institution was not human research because we analyzed publicly available data. This study has met all criteria for ethical standards regarding human studies as described in the 1964 Declaration of Helsinki and all amendments.
: Not applicable.
: ZZ is a member of the Editorial Board of BMC Musculoskeletal Disorders. The other authors declare that they have no competing interests. The OAI is a public–private partnership comprised of five contracts funded by the National Institutes of Health. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc.
